ClinicalTrials.gg
RecruitingNCT06733675Updated Nov 5, 2026

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

A Phase 1 interventional study of Ledaborbactam etzadroxil and Ceftibuten in Healthy Volunteer, Pharmacokinetics and Safety, sponsored by Basilea Pharmaceutica. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1, open-label, three-part, study in approximately 96 healthy adult participants between 18 and 55 years of age (both inclusive) (16 participants in Part 1, 20 participants in Part 2 and , and approximately 60 participants in Part 3). The study will be conducted at one clinical site in the United States. Participants in Part 1 and Part 2 may be conducted in parallel. The duration of an individual participation will be approximately 46 days for Part 1 , 43 days for Part 2 and 83 days for Part 3. All participants in Parts I und 2 will be screened within 28 days prior to dosing. All participants in Part 3 will be screened within 33 days prior to dosing. They will be admitted to the clinical research unit (CRU) the day prior to dosing and will remain in the CRU until the end of the PK sample collection period. All participants will return to the clinic for follow-up assessments 7 days ± 1 day after the last dose of study intervention. Participants in Part 3 will also return to the clinic for follow-up assessments 28 days ± 2 days and 42 days ± 2 days after the last dose of study intervention.

02

Conditions studied

  • Healthy Volunteer
  • Pharmacokinetics
  • Safety
  • Drug-Drug Interaction (DDI)
  • FDC

Keywords

  • Healthy Volunteers
  • Ceftibuten
  • Ledaborbactam etzadroxil
03

In context

Lead sponsor

Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult male or female, between 18 and 55 years of age
  • ≥ 18 and ≤ 32 kg/m2
  • Laboratory values meeting defined laboratory ranges
  • Males or non-pregnant, non-lactating females

Exclusion criteria

Exclusion Criteria:

  • History of any reaction following administration of a cephalosporin, penicillin, or other β-lactam antibacterial drug
  • Any acute illness or surgery within the past 3 months determined by the investigator to be
  • Positive alcohol, drug or tobacco use/test
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Part 1

    Part 1 will enroll at least 16 participants who will receive a single oral dose of ceftibuten and ledaborbactam etzadroxil following a 10-hour fast on 3 occasions in a fixed sequence: (a) Ceftibuten and ledaborbactam etzadroxil as separate capsules; (b) Ceftibuten-ledaborbactam etzadroxil as fixed-dose combination (FDC) capsules; (c) Ceftibuten-ledaborbactam etzadroxil as FDC capsules after 5 days of esomeprazole orally once daily

    Drug: Ledaborbactam etzadroxil · Drug: Ceftibuten · Drug: Ceftibuten-ledaborbactam etzadroxil · Drug: Esomeprazole

  • Experimental
    Part 2 Group 1

    Part 2 Group 1 will enroll 10 participants. Each will receive oral doses of Ceftibuten-ledaborbactam etzadroxil FDC capsules for 7 days (Fasted Group)

    Drug: Ceftibuten-ledaborbactam etzadroxil

  • Experimental
    Part 2 Group 2

    Part 2 Group 2 will enroll 10 participants. Each will receive oral doses of Ceftibuten-ledaborbactam etzadroxil FDC capsules for 7 days (Fed Group)

    Drug: Ceftibuten-ledaborbactam etzadroxil

  • Experimental
    Part 3 (Groups 1, 2, 4, 5, 6)

    Part 3 will enroll up to 50 participants. Each will receive oral doses of ceftibuten and/or ledaborbactam etzadroxil capsules (combined as FDC when administered together) in fed conditions

    Drug: Ledaborbactam etzadroxil · Drug: Ceftibuten

  • Active comparator
    Part 3 Group 3

    Part 3 Group 3 will enroll up to 10 participants. Each will receive oral doses of amoxicillin-clavulanate

    Drug: amoxicillin-clavulanate

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1 Plasma PK AUC0-∞ (ceftibuten, ledaborbactam, and ledaborbactam etzadroxil)

    Area under the concentration time curve from time zero to infinity (AUC0-∞)

    Time frame: 0 - 48 hours on days 1, 4 and 11

  2. Part 1 Plasma PK Cmax (ceftibuten, ledaborbactam, and ledaborbactam etzadroxil)

    Maximum observed concentration (Cmax)

    Time frame: 0 - 48 hours on days 1, 4 and 11

  3. Proportion of participants of Part 2 experiencing Treatment-emergent adverse events (TEAEs), Serious TEAEs, or TEAEs leading to discontinuation.

    Participants experiencing Treatment-emergent adverse events (TEAEs), Serious TEAEs, or TEAEs leading to discontinuation.

    Time frame: Day 1 thru Day 18 (+/-1)

  4. Proportion of participants of Part 3 experiencing Treatment-emergent adverse events (TEAEs), Serious TEAEs, or TEAEs leading to discontinuation.

    Participants experiencing Treatment-emergent adverse events (TEAEs), Serious TEAEs, or TEAEs leading to discontinuation.

    Time frame: Day 1 thru Day 49 (± 2 days)

Secondary outcomes

  1. Proportion of participants of Part 1 experiencing Treatment-emergent adverse events (TEAEs), Serious TEAEs, or TEAEs leading to discontinuation.

    Participants experiencing Treatment-emergent adverse events (TEAEs), Serious TEAEs, or TEAEs leading to discontinuation.

    Time frame: Day 1 thru Day 18 (+/-1)

  2. Part 2 Plasma PK AUC0-12h (ceftibuten, ledaborbactam, and ledaborbactam etzadroxil)

    Area under the concentration time curve from time zero to 12h (AUC0-12h)

    Time frame: Day 1 and Day 7

  3. Part 2 Plasma PK Cmax (ceftibuten, ledaborbactam, and ledaborbactam etzadroxil)

    Maximum observed concentration (Cmax)

    Time frame: Day 1 and Day 7

  4. Part 3 Plasma PK AUC0-Tau (ceftibuten and/or ledaborbactam)

    Area under the concentration time curve from time zero to Tau (AUC0-Tau)

    Time frame: At Day 1 and Day 7

  5. Part 3 Plasma PK Cmax (ceftibuten and/or ledaborbactam)

    Maximum observed concentration (Cmax)

    Time frame: At Day 1 and Day 7

07

Study locations

1 of 1 sites recruiting
  • ICON, Clinical Research Phase I Unit
    Lenexa, Kansas 66219, United States
    Recruiting
    • Daniel Dickerson, MD. PhD, FAAFP · ContactDaniel.Dickerson@iconplc.com · 913-205-4397
    • Daniel Dickerson, MD, PhD, FAAFP · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Dec 13, 2024
StartActual
Jan 7, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06733675
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Dec 13, 2024
Start date
Jan 7, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Nov 5, 2026

Study contacts

Karine Litherland, PhD
Contact
Karine.Litherland@basilea.com
+41616061111
Kamal Hamed, MD
study director · Basilea Pharmaceutica International Ltd, Allschwil

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ledaborbactam etzadroxil

Start the discussion